Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Investor Presentation (April 2025)
19 slides from Zelira Therapeutics's investor presentation, Apr 3, 2025
Slide 1: Zelira Therapeutics Investor Deck April 2025
For personal use only ZELIRA THERAPEUTICS Investor Deck April 2025 ASX: ZLD OTCQB:ZLDAF zeliratx.com
Slide 2: Company Overview
COMPANY OVERVIEW For personal use only Zelira is a global biopharmaceutical company developing, and marketing clinically validated cannabinoid-based medicines. It offers investors exposure to a rapidly emerging global industry at a very attractive valuation, with multiple shots on goal to create sig
Slide 3: Zelira's unique rapid commercialisation strategy
Zelira’s unique rapid commercialisation strategy For personal use only Launch Learn Develop Generate proprietary formulations Collect real-world patient data Patient data informs and de-risks Launch products in global markets Refine product to meet patient needs design of clinical trial Rapid path t
Slide 4: Zelira's portfolio of products: multiple shots on goal
Zelira’s portfolio of products: multiple shots on goal For personal use only PRODUCT Autism Insomnia Neuropathy Diabetic Nerve Pain Oral Care Dermatology HOPE® 1 ZENIVOL® iTURA™ ZLT-L-007 SprinJene RAV FIVE™ CLINICAL EVIDENCE/ De-risked lead World’s first clinically Consumers have Outperformed Helps
Slide 5: HOPE 1: A proven and de-risked lead candidate
HOPE® 1: A proven and de-risked lead candidate For personal use only About HOPE®1 Clinically validated, highly Near-term development de-risked ASD treatment milestones Launched in US in 2020 and then Over 11 Million doses of HOPE® 1 dispensed Initial focus - Phelan McDermid Syndrome Australia under
Slide 6: ASD is highly prevalent with ineffective current therapies
ASD is highly prevalent with ineffective current therapies that carry significant risks For personal use only Desiree to around so Prevalence Existing Therapies have Significant Risks About 1 in 44 children identified with Autism Current treatments are antipsychotic drugs, Spectrum Disorder (ASD)1 S
Slide 7: Real world evidence – HOPE improved CGI and Efficacy Score in ASD patients
Real world evidence – HOPE® 1 improved Clinical Global Impression (CGI) and Efficacy Score in ASD patients CGI Global Improvement For personal use only 100% By 5 months, % of patients as rated by the clinician 100% of the patients showed 80% improvement 60% 40% After 1 month, 56% showed minimal impr
Slide 8: Development pathway for HOPE Phelan McDermid Syndrome program
Development pathway for HOPE® 1 Phelan McDermid Syndrome (PMS) co-morbid with ASD program Phelan-McDermid Syndrome (PMS) Regulatory Pathway For personal use only Ultra-rare genetic condition caused by a deletion or change of Accelerated regulatory pathway strategy utilizing existing pre- chromosome
Slide 9: HOPE development pathway for indications within ASD subset
HOPE® 1 and HOPE® 2 development pathway for indications within Autism Spectrum Disorder (ASD) subset Target Indication Subset Targets Co-morbid with ASD For personal use only 2025 2026 2027 Initial focus with fund raise IND and Phase 2 Phase 1/ Phase 3 Reduction in Irritability Phelan McDermid Syndr
Slide 10: Zelira Catalyst for Growth: Outlook
ZELIRA CATALYST FOR GROWTH Outlook For personal use only • Commencement of Phase 1 clinical trials for HOPE® 1 • Development work for the transformation of Zenivol® into a capsule formulation is on track to be completed in mid-late 2025 • Evaluating the further progression of ZLT-L-007 into formal F
Slide 11: Investment highlights
Investment highlights For personal use only De-risked, proven lead candidate Multiple shots on goal DeriskedRx & OTC Development and Commercialisation strategies HOPE® 1 already proven to be effective in Leading pipeline of products in clinical treating Autism Spectrum Disorder (ASD); development fo
Slide 12: Disclaimer & Important Notice
DISCLAIMER & IMPORTANT NOTICE Disclaimer Future Matters For personal use only This presentation has been prepared by Zelira affairs, financial position or prospects of the Company. This presentation contains reference to certain intentions, Therapeutics Ltd ACN 103 782 378 (“Company”). It The Compan
Slide 13: Thank You
Thank You For personal use only For further information please contact Company Investors Dr Oludare Odumosu Gabriella Hold Managing Director & CEO Executive Director, Automic Group +1 909 855 0675 +61 411 364 382 oodumosu@zeliratx.com gabriella.hold@automicgroup.com.au Zelira Therapeutics Phone +1 4
Slide 14: Appendix
For personal use only Appendix 14
Slide 15: 1H FY25 Milestones
1H FY25 Milestones 2024 2025 8 Jan 24 28 Jan 25 Zelira’s HOPE® SPV receives US$819,000 Zelira’s HOPE® receives US$681,000 For personal use only second tranche of funding fourth tranche of funding 15 Apr 24 18 Feb 25 Zelira receives $919,000 R&D Tax Incentive Scheme refund Zelira receives $1,153,000
Slide 16: ZENIVOL for chronic, unresolved insomnia
ZENIVOL® for chronic, unresolved insomnia Overview • World’s first clinically Insomnia Market validated cannabinoid • 30% of adults report symptoms of insomnia1 drug for chronic insomnia For personal use only • US insomnia market: US $4B by 20212 • Phase 1B/2A clinical trial • Current medications li
Slide 17: Zelira's Diabetic Nerve Pain Drug (ZLT-L-007) Outperforms Lyrica
Zelira’s Diabetic Nerve Pain Drug (ZLT-L-007) Outperforms Big Pharma drug; successful clinical trial against multi-billion-dollar Lyrica® Demonstrated Safety, Tolerability, and Improved Efficacy For personal use only Objective of the study Topline Results Market Potential • Comparing Zelira’s patent
Slide 18: ZYRAYDI Enhanced Cannabinoid Capture and Dissolution Matrix
ZYRAYDI™ (Enhanced Cannabinoid Capture and Dissolution Matrix) For personal use only DIFFICULTY WITH FORMULATION AND DEVELOPMENTS OF FREE FLOW CAP- CANNABINOID SULES AND TABLETS DUE TO NON • Breakthrough technology developed by Zelira DISTILLATE UNIFORMITY AND SEPARATING FROM POWDER BED • Solves the
Slide 19: Global Board of Directors
Global Board of Directors For personal use only USA GLOBAL USA AUS AUS Osagie Imasogie Dr. Oludare Odumosu Dr Donna Gentile O’Donnell Tim Slate Greg Blake Chairman Global CEO Non-Executive Director Non-Executive Director Executive Director • Over 30 years in the field • Post-clinical development • S
Zelira Therapeutics — Investor Presentation (April 2025) on 6ix